Matthew Durdy

Addressing remaining barriers to the commercialization of ATMPs 2:07
Addressing remaining barriers to the commercialization of ATMPs
Matthew Durdy • 6 Oct 2021
The evolving landscape of autologous and allogeneic therapies 1:44
The evolving landscape of autologous and allogeneic therapies
Matthew Durdy • 6 Oct 2021
An update on the UK Cell and Gene Therapy Catapult 2:21
An update on the UK Cell and Gene Therapy Catapult
Matthew Durdy • 6 Oct 2021
What can the advanced therapies industry learn from the COVID-19 pandemic? 1:44
What can the advanced therapies industry learn from the COVID-19 pandemic?
Matthew Durdy • 6 Oct 2021
The current landscape of advanced therapies in the UK 1:34
The current landscape of advanced therapies in the UK
Matthew Durdy • 6 Oct 2021
Building the advanced therapies workforce in the UK 4:25
Building the advanced therapies workforce in the UK
Matthew Durdy • 9 Apr 2021
The state of investment in cell & gene therapy 3:31
The state of investment in cell & gene therapy
Matthew Durdy • 9 Apr 2021
Tackling manufacturing challenges in advanced therapies 3:35
Tackling manufacturing challenges in advanced therapies
Matthew Durdy • 9 Apr 2021
Harmonizing standards in the advanced therapy industry 4:03
Harmonizing standards in the advanced therapy industry
Matthew Durdy • 9 Apr 2021
The content of VJRegenMed is intended for healthcare professionals